Phasebio Pharmaceuticals Inc., of Malvern, Pa., said it closed its underwritten public offering of 4.12 million shares that included 537,975 shares from the full exercise of the underwriters' option to purchase additional shares at $12 each. The gross proceeds from the offering were $49.5 million.